Previous Article | Back To List | Next Article

Hot Topics on Subcutaneous Methotrexate in Rheumatoid Arthritis

medac EULAR satellite symposium in London: International experts share experiences on MTX therapy, biosimilars, cardioprotective effects and patient adherence

London / Wedel (09 June 2016)

What are the current best-practice strategies using subcutaneous methotrexate in rheumatoid arthritis? Has the value of methotrexate as anchor drug changed in the age of biologicals and biosimilars? What is known about the effects and mechanisms conveyed by methotrexate (MTX) on the cardiovascular system? How can rheumatologists influence patient adherence?

These current topics in the field of rheumatology will be covered by this year’s EULAR satellite symposium held by medac, the world-wide leading provider of subcutaneous methotrexate.

“We are very much looking forward to the symposium,” states Heiner Will, Managing Director of medac. “Especially due to the participation of the former ACR president, Dr. Stanley Cohen, United States, who is going to share his expertise on subcutaneous methotrexate in daily practice. It has been published that MTX remains frequently under-dosed1; but nevertheless the potential of subcutaneous methotrexate improving RA therapy is increasingly recognized and applied in practice.”

The topic of methotrexate in the age of biosimilars and biologic drugs will be outlined by well-known Prof. Jürgen Braun, Germany. He had conducted the ground-breaking clinical trial showing that the parenteral MTX was more effective than the oral administration2. Usually, MTX increases the effectiveness of biologic agents in rheumatoid arthritis3, and also its advantageous cost-effectiveness persist in the presence of biosimilars4.

The important aspects of patient adherence or non-adherence to therapy and the role of the rheumatologists are going to be discussed by Prof. Johanna Hazes, the Netherlands. Her publications stress the value of open and trustworthy relationships between rheumatologists and patients5. Good relationships may enable discussing non-adherence issues and thus help the patient to focus on the treatment goal.

Another important highlight of the symposium will be the input provided by Prof. Evgeny Nasonov, Russian Federation, who is going to present recent insights in the cardioprotective mechanism of MTX6. The inflammatory events of RA are known to contribute to cardiovascular risk factors. Various hypothetical mechanisms will be discussed how methotrexate deploys its cardioprotective effects.

References

  1. O’Dell JR et al., Arthritis Rheumatol. 2015; 67 (suppl 10): ACR 2015 Abstract Number 1997

  2. Braun J et al., Arthritis Rheum 2008;58:73-81

  3. Nam JL et al., Ann Rheum Dis 2010;69:976-986

  4. Fitzpatrick R et al., Clin Rheumatol. 2013;32:1605-1612

  5. Pasma A et al., Arthritis Res Ther 2015;17:281

  6. Popkova TV et al., Curr Med Chem 2015; 22:1903-1910

About Medac Pharma: Practicing a patient-first philosophy

Medac Pharma, Inc. is a privately held specialty pharmaceutical company focused on the development, in-licensing and commercialization of late-stage molecules. The company strives to bring new life to products and solve everyday patient challenges in autoimmune disease and cancer.

Medac Pharma is the wholly-owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years. For more information about medac GmbH, please visit www.medac.de.

For complete prescribing information, including Boxed Warning, and information on Medac Pharma’s CORE Connections program, please visit www.Rasuvo.com.